In a significant move aimed at tackling treatment-resistant cancers, global contract research, development, and manufacturing organization (CRDMO) WuXi XDC has announced a new out-licensing agreement with the biotechnology firm Ona Therapeutics. The partnership centers on the utilization of WuXi XDC’s proprietary “WuXiTecan-2” payload-linker technology platform, a key component in the development of next-generation antibody-drug conjugates (ADCs).
Under the terms of the deal, Ona Therapeutics has been granted an exclusive license to incorporate the WuXiTecan-2 platform into the development of an ADC candidate targeting a specific, undisclosed protein associated with aggressive, drug-resistant malignancies. While the precise financial details of the agreement remain confidential, the contract includes an initial upfront payment alongside a series of milestone payments contingent upon successful development, regulatory approvals, and eventual sales targets. Furthermore, should the program reach commercialization, WuXi XDC is set to receive tiered royalties on global net sales.
Beyond providing the core technology, WuXi XDC will serve as a strategic partner throughout the lifecycle of the candidate. The firm is slated to provide comprehensive chemistry, manufacturing, and controls (CMC) development, as well as manufacturing support to move the product through the regulatory pipeline.
This agreement marks the second time the two companies have joined forces within the burgeoning ADC field. In 2024, Ona Therapeutics previously licensed technologies from WuXi XDC to bolster its existing pipeline. According to both parties, the decision to deepen their collaboration reflects a shared commitment to accelerating the transition of promising therapies from the laboratory into clinical settings.
“We are truly honored to join forces once again with Ona Therapeutics,” said Dr. Jimmy Li, CEO of WuXi XDC. “Ona’s deep insights into novel targets are highly complementary to WuXi XDC’s leading ADC technology platforms. We look forward to fully supporting Ona Therapeutics in accelerating this first-in-class ADC candidate into the clinic.”
Dr. Valerie Vanhooren, co-founder and CEO of Ona Therapeutics, echoed this sentiment, describing the new deal as a pivotal milestone for her company’s research goals. “Our previous collaboration established a strong foundation,” Vanhooren noted. “We are pleased to build on that relationship as we work to accelerate this promising program toward the clinic.”
The oncology sector has seen an explosion of interest in ADCs, often described as “guided missiles” of the cancer world because they deliver potent chemotherapy agents directly to tumor cells while sparing healthy tissue. By targeting treatment-resistant cancers, which historically present limited therapeutic options for patients, this collaboration highlights the growing trend of leveraging modular technology platforms to fast-track precision medicines. As the program progresses, both companies hope to provide new hope for patients facing limited treatment avenues, leveraging their combined technical expertise to address some of the most stubborn challenges in modern oncology.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
